| Cubicin (daptomycin) / Merck (MSD) |
NCT00055198: Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria |
|
|
| Terminated | 3 | 75 | NA | daptomycin | Cubist Pharmaceuticals LLC | Gram-Positive Bacterial Infections | 01/04 | 01/04 | | |
NCT00093067: Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus |
|
|
| Completed | 3 | | NA | daptomycin | Cubist Pharmaceuticals LLC | Bacterial Endocarditis, Bacteremia | 11/04 | 02/05 | | |
NCT00430937: Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections |
|
|
| Terminated | 3 | 194 | Europe | Daptomycin, Cubicin, Vancomycin, Vancocin, Teicoplanin, Targocid | Novartis Pharmaceuticals | Skin Diseases, Infectious, Soft Tissue Infections | 03/08 | | | |
NCT00770341: A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) |
|
|
| Completed | 3 | 122 | NA | Daptomycin 4 mg/kg, MK3009, Comparator: vancomycin, Daptomycin 6 mg/kg | Merck Sharp & Dohme LLC | Staphylococcal Infection | 02/10 | 02/10 | | |
NCT00772447: China Registration Study in Patients With Skin Infections |
|
|
| Completed | 3 | 265 | RoW | Daptomycin, Cubicin®, Vancomycin | AstraZeneca | Skin Diseases, Infectious | 09/10 | 09/10 | | |
NCT00701636: Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery |
|
|
| Completed | 3 | 30 | US | daptomycin, Cubicin | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Cubist Pharmaceuticals LLC, Hartford Hospital, Western University of Health Sciences | Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection | 10/10 | 10/10 | | |
NCT01184872 / 2009-014391-22: Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections |
|
|
| Completed | 3 | 120 | Europe, RoW | Daptomycin, Vancomycin or Semi-Synthetic Penicillins (SSPs), Oxacillin,, Cloxacillin,, Flucloxacillin, | Novartis Pharmaceuticals | Infections | 03/11 | 03/11 | | |
DAVASAB, NCT01515020: Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia |
|
|
| Terminated | 3 | 10 | Europe | vancomycin monotherapy, intravenous therapy, daptomycin monotherapy | Assistance Publique - Hôpitaux de Paris, Novartis | Nosocomial Infection, Healthcare-associated Infection | 06/13 | 07/14 | | |
DAPTOREA, NCT02142075: Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure |
|
|
| Completed | 3 | | Europe | Daptomycin | Poitiers University Hospital | Renal Failure, Critical Care, Gram Positive Bacteria | 09/15 | | | |
| Completed | 3 | 149 | NA | Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent) | Cubist Pharmaceuticals LLC | Acute Hematogenous Osteomyelitis | 06/16 | 12/16 | | |
| Completed | 3 | 167 | Europe | Fosfomycin 2gr/6h iv, Daptomycin 10mg/kg/24h iv | Miquel Pujol, Hospital Universitari de Bellvitge | Staph Aureus Methicillin Resistant Bacteremia | 01/18 | 01/18 | | |
NCT01455246: Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis |
|
|
| Terminated | 2/3 | 32 | Europe | Daptomycin + Meropenem, Ceftazidime | University of Padova | Cirrhosis, Ascites, Nosocomial Spontaneous Bacterial Peritonitis | 04/14 | 07/14 | | |
